At NAC completion, pCR was observed in 84 out of 266 (31%) patients and pCR rates were significantly different by BC subtype (luminal: 10% (9/89), TNBC: 45% (49/110) and HER2-positive 39% (26/67), p < 0.001). The gene discussed is ERBB2; the disease is breast cancer.